haloperidol has been researched along with Chemical Dependence in 78 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 6.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome." | 5.40 | Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014) |
| "Cocaine cues significantly increased anxiety, ACTH, cortisol, and HVA." | 5.08 | Haloperidol antagonism of cue-elicited cocaine craving. ( Berger, SP; Carr, K; Crawford, CA; Delucchi, K; Hall, S; Mickalian, JD; Reid, MS, 1996) |
| "Eighteen patients (7 men, 11 women) from one of the centres taking part in a multicentre comparative study of remoxipride and haloperidol in the treatment of acute schizophrenia were investigated separately to study the effect of the two neuroleptic drugs on cognitive abilities." | 5.06 | Cognitive disturbances in neuroleptic therapy. ( Klieser, E; Strauss, WH, 1990) |
| " When the diagnosis of haloperidol-induced acute dystonia was made, 3 mg of intravenous biperiden was promptly administered with complete clinical resolution in 15 min." | 3.91 | Involuntary movements in an adolescent: what are the causes? ( Brito, N; Fernandes, A; Moura, L; Vaz, AS, 2019) |
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 2.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "The technical term 'drug dependence' was officially adopted by WHO's Expert Committee on Addiction in 1964." | 2.38 | [Overview of the progress in drug dependence studies--mainly focussing on psychic dependence]. ( Yanagita, T, 1992) |
| "Treatment with carisoprodol and phenobarbital provided additional benefit and can be considered in cases of severe carisoprodol withdrawal." | 1.46 | Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. ( Benowitz, NL; Horng, H; Smollin, CG; Vo, KT, 2017) |
| "Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome." | 1.40 | Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "Cariprazine (RGH-188) is a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate for the treatment of schizophrenia and bipolar mania." | 1.39 | Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. ( Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z, 2013) |
| "Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003." | 1.34 | Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. ( Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B, 2007) |
| " Chronic administration of many DA antagonists alters dopaminergic function, causing a supersensitivity to DA agonists." | 1.30 | Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. ( Kosten, TA, 1997) |
| "We report a patient with drug abuse who developed multiple psychotic symptoms including euphoria, excitement, hallucination and delirium during sedation with propofol under spinal anesthesia." | 1.30 | [A patient with drug abuse who developed multiple psychotic symptoms during sedation with propofol]. ( Kitajima, T; Mishio, M; Okuda, Y; Yamaguchi, S, 1998) |
| "In many organic psychoses, including psychosis due to ingestion of an atropine-like drug, use of anti-psychotic drug should be avoided." | 1.25 | Psychotropic drugs in the management of psychiatric emergencies. ( Ketai, R, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (47.44) | 18.7374 |
| 1990's | 18 (23.08) | 18.2507 |
| 2000's | 12 (15.38) | 29.6817 |
| 2010's | 10 (12.82) | 24.3611 |
| 2020's | 1 (1.28) | 2.80 |
| Authors | Studies |
|---|---|
| Lindsley, CW | 1 |
| Hopkins, CR | 1 |
| Vaz, AS | 1 |
| Brito, N | 1 |
| Moura, L | 1 |
| Fernandes, A | 1 |
| Arranz, B | 1 |
| Garriga, M | 1 |
| Bernardo, M | 1 |
| González-Pinto, A | 1 |
| Arrojo, M | 1 |
| Torrens, M | 1 |
| Tirado-Muñoz, J | 1 |
| Fonseca, F | 1 |
| Sáiz, PA | 1 |
| Flórez, G | 1 |
| Goikolea, JM | 1 |
| Zorrilla, I | 1 |
| Cunill, R | 1 |
| Castells, X | 1 |
| Becoña, E | 1 |
| López, A | 1 |
| San, L | 1 |
| Hardman, MI | 1 |
| Sprung, J | 1 |
| Weingarten, TN | 1 |
| Uys, H | 1 |
| Oluwole, LO | 1 |
| Dada, MU | 1 |
| Obadeji, A | 1 |
| Mesholam-Gately, RI | 1 |
| Gibson, LE | 1 |
| Seidman, LJ | 1 |
| Green, AI | 2 |
| Vo, KT | 1 |
| Horng, H | 1 |
| Smollin, CG | 1 |
| Benowitz, NL | 1 |
| MacDonald, K | 1 |
| Wilson, M | 1 |
| Minassian, A | 1 |
| Vilke, GM | 1 |
| Becker, O | 1 |
| Tallian, K | 1 |
| Cobb, P | 1 |
| Perez, R | 1 |
| Galangue, B | 1 |
| Feifel, D | 1 |
| Bédard, AM | 1 |
| Maheux, J | 1 |
| Lévesque, D | 1 |
| Samaha, AN | 1 |
| Román, V | 1 |
| Gyertyán, I | 2 |
| Sághy, K | 1 |
| Kiss, B | 1 |
| Szombathelyi, Z | 1 |
| Gál, K | 1 |
| Wynchank, D | 1 |
| Berk, M | 1 |
| Suetsugu, S | 1 |
| Morita, N | 1 |
| Alevizos, B | 1 |
| Tohen, MF | 1 |
| Hamer, RM | 1 |
| Strakowski, SM | 1 |
| Lieberman, JA | 1 |
| Glick, I | 1 |
| Clark, WS | 1 |
| Jung, IK | 1 |
| Lee, HJ | 1 |
| Cho, BH | 1 |
| Papazisis, G | 1 |
| Kouvelas, D | 1 |
| Mastrogianni, A | 1 |
| Karastergiou, A | 1 |
| Potvin, S | 1 |
| Mancini-Marïe, A | 1 |
| Fahim, C | 1 |
| Mensour, B | 1 |
| Lévesque, J | 1 |
| Karama, S | 1 |
| Beauregard, M | 1 |
| Rompré, PP | 1 |
| Stip, E | 1 |
| Shi, L | 1 |
| Ascher-Svanum, H | 1 |
| Zhu, B | 1 |
| Faries, D | 1 |
| Montgomery, W | 1 |
| Marder, SR | 1 |
| Kantrowitz, JT | 1 |
| Srihari, VH | 1 |
| Tek, C | 1 |
| Fuchs, V | 1 |
| Burbes, E | 1 |
| Coper, H | 1 |
| Buhrich, N | 1 |
| Morris, G | 1 |
| Cook, G | 1 |
| Penn, JR | 1 |
| Mackenzie, TB | 1 |
| Jack, RA | 1 |
| Kaufmann, M | 1 |
| Kahaner, K | 1 |
| Peselow, ED | 1 |
| Gershon, S | 2 |
| Weddington, WW | 1 |
| Leventhal, BL | 1 |
| Kulik, AV | 1 |
| Wilbur, R | 1 |
| Busch, KT | 1 |
| Schulz, H | 1 |
| Risberg, J | 1 |
| Doenecke, AL | 1 |
| Heuermann, RC | 1 |
| LeDuc, PA | 1 |
| Mittleman, G | 1 |
| Richardson, NR | 1 |
| Smith, AM | 1 |
| Roberts, DC | 1 |
| Patel, A | 1 |
| Getsos, JP | 1 |
| Moussa, G | 1 |
| Damato, AN | 1 |
| Shenoy, RS | 1 |
| Tesar, GE | 1 |
| Stone, AM | 1 |
| Greenstein, RA | 1 |
| Gamble, G | 1 |
| McLellan, AT | 1 |
| Berger, SP | 1 |
| Hall, S | 2 |
| Mickalian, JD | 1 |
| Reid, MS | 1 |
| Crawford, CA | 1 |
| Delucchi, K | 1 |
| Carr, K | 1 |
| Ettenberg, A | 1 |
| MacConell, LA | 1 |
| Geist, TD | 1 |
| Kuribara, H | 1 |
| Sekine, H | 1 |
| Nakahara, Y | 1 |
| Kosten, TA | 1 |
| Yamaguchi, S | 1 |
| Mishio, M | 1 |
| Okuda, Y | 1 |
| Kitajima, T | 1 |
| Hernandez-Avila, CA | 1 |
| Ortega-Soto, HA | 1 |
| Jasso, A | 1 |
| Hasfura-Buenaga, CA | 1 |
| Kranzler, HR | 1 |
| Thomas, MJ | 1 |
| Malenka, RC | 1 |
| Bonci, A | 1 |
| Göpel, C | 1 |
| Laufer, C | 1 |
| Marcus, A | 1 |
| Lal, H | 1 |
| Snyder, R | 1 |
| Eldore, A | 1 |
| Zylber-Katz, E | 1 |
| de-Nour, AK | 1 |
| Lee, AS | 1 |
| Greenblatt, DJ | 1 |
| Gross, PL | 1 |
| Harris, J | 1 |
| Shader, RI | 1 |
| Ciraulo, DA | 1 |
| Gruner, E | 1 |
| Hefez, A | 1 |
| Allen, RM | 1 |
| Young, SJ | 1 |
| Kocur, J | 1 |
| Ketai, R | 1 |
| Akpaffiong, MJ | 1 |
| Yanagita, T | 1 |
| Nambudiri, DE | 1 |
| Young, RC | 1 |
| Bowers, MB | 1 |
| Mazure, CM | 1 |
| Nelson, JC | 1 |
| Jatlow, PI | 1 |
| Strauss, WH | 1 |
| Klieser, E | 1 |
| Sabet-Sharghi, F | 1 |
| Hutzler, JC | 1 |
| Shalev, A | 1 |
| Hermesh, H | 1 |
| Munitz, H | 1 |
| Goldney, R | 1 |
| Bowes, J | 1 |
| Spence, N | 1 |
| Czechowicz, A | 1 |
| Hurley, R | 1 |
| Kumor, K | 1 |
| Sherer, M | 1 |
| Jaffe, J | 1 |
| van der Laan, JW | 1 |
| Hillen, FC | 1 |
| Aravena, R | 1 |
| Torres, R | 1 |
| Sherer, MA | 1 |
| Hoffman, AS | 1 |
| Schwartz, HI | 1 |
| Novick, RM | 1 |
| Pozuelo, J | 1 |
| Kerr, FW | 1 |
| Carranza-Acevedo, J | 1 |
| Estrada-Robles, U | 1 |
| Duncan, JW | 1 |
| Angrist, B | 1 |
| Lee, HK | 1 |
| LeCompte, G | 1 |
| Friedman, JJ | 1 |
| Sinacore, R | 1 |
| Modestin, J | 1 |
| Moskowitz, D | 1 |
| Melikian, V | 1 |
| Eddy, JD | 1 |
| Paton, A | 1 |
| Voelkel, A | 1 |
| Sigell, LT | 1 |
| Flessa, HC | 1 |
| Hezar-Khani, F | 1 |
| Vogelberg, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Clonidine on Responses to Imagery Scripts[NCT00318760] | Phase 1 | 92 participants (Actual) | Interventional | 2005-06-14 | Completed | ||
| Effects of Propranolol on Responses to Drug-Related Imagery Scripts[NCT00688805] | Phase 1 | 40 participants (Actual) | Interventional | 2007-12-12 | Terminated | ||
| PET Assays of Striatal Dopamine Markers in Cocaine Craving[NCT01036516] | 14 participants (Anticipated) | Observational | 1998-06-23 | Completed | |||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
8 reviews available for haloperidol and Chemical Dependence
| Article | Year |
|---|---|
Return of D
Topics: Animals; Drug Discovery; Humans; Ligands; Molecular Targeted Therapy; Neoplasms; Parkinson Disease; | 2017 |
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor | 2019 |
[Organic solvent-related mental disorders].
Topics: Administration, Inhalation; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Haloperidol; Human | 2003 |
The agitated patient, Part II: Pharmacologic treatment.
Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Emergencies; Haloperidol; Humans; Lorazepam; Neu | 1993 |
Narcotic dependence, narcotic action and dopamine receptors.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Cyclic AMP; Dopam | 1975 |
[Overview of the progress in drug dependence studies--mainly focussing on psychic dependence].
Topics: Animals; Benzodiazepines; Haloperidol; Humans; Limbic System; Methadone; Naloxone; Receptors, Dopami | 1992 |
Mortality from neuroleptic malignant syndrome.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dantrolene; Dopamine Agents; Female; Haloperidol; | 1989 |
[Alcoholic psychoses: therapeutic schemes].
Topics: Alcohol Withdrawal Delirium; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlormethia | 1988 |
7 trials available for haloperidol and Chemical Dependence
| Article | Year |
|---|---|
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease | 2003 |
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Topics: Adolescent; Adult; Benzodiazepines; Comorbidity; Diagnostic and Statistical Manual of Mental Disorde | 2004 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Haloperidol antagonism of cue-elicited cocaine craving.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anxiety; Cocaine; Conditioning, Psychological; Cross | 1996 |
Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Dyskinesia, Drug-Induced; Haloperidol; | 1998 |
Haloperidol in barbiturate detoxification.
Topics: Adolescent; Adult; Barbiturates; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Fem | 1977 |
Cognitive disturbances in neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Benzamides; Cognition Disorders; Double-Blind Method; Haloperidol; Huma | 1990 |
The antagonism of amphetamine-induced symptomatology by a neuroleptic.
Topics: Amphetamine; Brain Chemistry; Clinical Trials as Topic; Dopamine; Dopamine Antagonists; Dose-Respons | 1974 |
63 other studies available for haloperidol and Chemical Dependence
| Article | Year |
|---|---|
Involuntary movements in an adolescent: what are the causes?
Topics: Adolescent; Alcoholic Intoxication; Antipsychotic Agents; Biperiden; Dystonia; Emergency Service, Ho | 2019 |
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Nicotine; Olanzapine; Practice Gu | 2022 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Self-inflicted bilateral orchidectomy precipitated by erotic bizarre delusions: a case report.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Prognosis; Recurrence; Schizophrenia, Parano | 2013 |
Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged | 2014 |
Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose.
Topics: Adult; Carisoprodol; Dexmedetomidine; Drug Overdose; Fentanyl; Haloperidol; Humans; Hypnotics and Se | 2017 |
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug | 2012 |
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Conditioning, Classic | 2013 |
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agoni | 2013 |
Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference.
Topics: Animals; Avoidance Learning; Benzazepines; Benzopyrans; Cocaine; Conditioning, Classical; Dopamine A | 2003 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimul | 2003 |
Persistent psychotic disorder in an adolescent with a past history of butane gas dependence.
Topics: Adolescent; Antipsychotic Agents; Butanes; Diagnostic and Statistical Manual of Mental Disorders; Ha | 2004 |
Anabolic androgenic steroid abuse and mood disorder: a case report.
Topics: Adult; Anabolic Agents; Antipsychotic Agents; Bipolar Disorder; Haloperidol; Humans; Impulsive Behav | 2007 |
Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study.
Topics: Adult; Antipsychotic Agents; Cell Count; Corpus Striatum; Diagnostic and Statistical Manual of Menta | 2007 |
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Black People; Cohort Studies; Comorbi | 2007 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 2007 |
The influence of haloperidol and aminooxyacetic acid on etonitazene, alcohol, diazepam and barbital consumption.
Topics: Acetates; Alcohol Drinking; Aminooxyacetic Acid; Animals; Barbital; Barbiturates; Benzimidazoles; Br | 1984 |
Bromo-DMA: the Australasian hallucinogen?
Topics: Adult; Amphetamines; Australia; DOM 2,5-Dimethoxy-4-Methylamphetamine; Female; Hallucinogens; Halope | 1983 |
Organic mental disorder associated with metrizamide.
Topics: Female; Haloperidol; Humans; Metrizamide; Middle Aged; Substance-Related Disorders | 1983 |
Unintentional haloperidol abuse.
Topics: Adult; Diazepam; Female; Haloperidol; Humans; Substance-Related Disorders | 1982 |
Steroid psychoses: case report and brief overview.
Topics: Adult; Dose-Response Relationship, Drug; Female; Giant Cell Arteritis; Haloperidol; Humans; Predniso | 1982 |
Malicious abuse of haloperidol.
Topics: Haloperidol; Humans; Prisoners; Substance-Related Disorders | 1982 |
Delirium and stereotypy from anticholinergic antiparkinson drugs.
Topics: Adult; Aged; Benztropine; Delirium; Diazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; E | 1982 |
[The acute psychiatric emergency].
Topics: Acute Disease; Aged; Alcoholism; Amitriptyline; Brain Ischemia; Cognition Disorders; Consciousness D | 1981 |
Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry.
Topics: Adult; Affective Symptoms; Aged; Alcoholism; Cerebrovascular Circulation; Computers; Dementia; Femal | 1980 |
Treatment of haloperidol abuse with diphenhydramine.
Topics: Adolescent; Adult; Alcohol Drinking; Diazepam; Diphenhydramine; Female; Haloperidol; Humans; Male; S | 1980 |
Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations.
Topics: Animals; Behavior, Animal; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug I | 1993 |
A single injection of either flupenthixol decanoate or haloperidol decanoate produces long-term changes in cocaine self-administration in rats.
Topics: Animals; Cocaine; Flupenthixol; Haloperidol; Injections, Intramuscular; Male; Rats; Rats, Wistar; Re | 1994 |
The Osborn wave of hypothermia in normothermic patients.
Topics: Adult; Aged; Angina Pectoris; Body Temperature; Chest Pain; Cocaine; Electrocardiography; Female; Ha | 1994 |
Pitfalls in the treatment of jimsonweed intoxication.
Topics: Adolescent; Contraindications; Datura stramonium; Drug Therapy, Combination; Haloperidol; Humans; Lo | 1994 |
Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
Topics: Adult; Ambulatory Care; Chronic Disease; Cocaine; Combined Modality Therapy; Comorbidity; Delayed-Ac | 1993 |
Effects of haloperidol in a response-reinstatement model of heroin relapse.
Topics: Animals; Dopamine Antagonists; Extinction, Psychological; Haloperidol; Heroin; Male; Narcotics; Rats | 1996 |
Characteristics of behavioural stimulant effect of N-cyanomethylmethamphetamine, a main product of smoking methamphetamine mixed with tobacco: evaluation by ambulatory activity in mice.
Topics: Amphetamines; Animals; Behavior, Animal; Central Nervous System Stimulants; Dopamine Antagonists; Do | 1996 |
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats.
Topics: Animals; Antipsychotic Agents; Cocaine; Discrimination, Psychological; Dopamine; Dopamine Antagonist | 1997 |
[A patient with drug abuse who developed multiple psychotic symptoms during sedation with propofol].
Topics: Adult; Anesthesia, Spinal; Antipsychotic Agents; Haloperidol; Humans; Hypnotics and Sedatives; Intra | 1998 |
Modulation of long-term depression by dopamine in the mesolimbic system.
Topics: Animals; Benzazepines; Conditioning, Psychological; Dopamine; Dopamine Agonists; Dopamine Antagonist | 2000 |
Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers.
Topics: Adolescent; Alkaloids; Antipsychotic Agents; Charcoal; Cholinergic Antagonists; Hallucinogens; Halop | 2002 |
Anticoagulant abuse: a psychotic syndrome?
Topics: Adult; Denial, Psychological; Diagnosis, Differential; Female; Haloperidol; Hemorrhage; Humans; Psyc | 1979 |
Treatment of drug-induced dystonic reactions.
Topics: Adolescent; Adult; Benztropine; Diphenhydramine; Dystonia; Female; Haloperidol; Humans; Injections, | 1979 |
Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.
Topics: Adult; Barbiturates; Dose-Response Relationship, Drug; Fever; Haloperidol; Humans; Male; Methaqualon | 1978 |
[Combined haloperidol and scopolamine for tranquilization of extremely restless patients].
Topics: Barbiturates; Drug Combinations; Haloperidol; Humans; Psychomotor Agitation; Scopolamine; Substance- | 1978 |
Phencyclidine-induced psychosis.
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Military Medicine; Phencyclidine; Psychoses, S | 1978 |
[Some psychotoxicological problems exemplified by lysergic acid diethylamide].
Topics: Adolescent; Age Factors; Animals; Haloperidol; Humans; Lysergic Acid Diethylamide; Phenoxybenzamine; | 1975 |
Psychotropic drugs in the management of psychiatric emergencies.
Topics: Administration, Oral; Amphetamine; Chlorpromazine; Hallucinogens; Haloperidol; Humans; Hypotension; | 1975 |
Risk factors for neuroleptic malignant syndrome.
Topics: Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium; Neuroleptic Malignant Syndro | 1992 |
A case of late-onset crack dependence and subsequent psychosis in the elderly.
Topics: Crack Cocaine; Delusions; Hallucinations; Haloperidol; Humans; Male; Middle Aged; Psychoses, Substan | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Prophylaxis of steroid-induced psychiatric syndromes.
Topics: Adult; Dibenzocycloheptenes; Female; Haloperidol; Humans; Lithium; Prednisone; Protriptyline; Substa | 1990 |
The psychiatric intensive care unit.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Australia; Critical Care; Female; Halop | 1985 |
Haloperidol-induced dystonia in cocaine addicts.
Topics: Adult; Cocaine; Dystonia; Haloperidol; Humans; Male; Substance-Related Disorders | 1986 |
The potentiation of morphine-withdrawal jumping by clonidine is antagonized by m-chlorophenylpiperazine and not by haloperidol.
Topics: Adrenergic alpha-Antagonists; Animals; Azepines; Behavior, Animal; Clonidine; Dopamine Antagonists; | 1986 |
Intravenous cocaine: psychiatric effects, biological mechanisms.
Topics: Adult; Arousal; Brain; Chromatography, High Pressure Liquid; Cocaine; Dose-Response Relationship, Dr | 1988 |
Catatonic reaction to accidental haloperidol overdose: an unrecognized drug abuse risk.
Topics: Adult; Catatonia; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Substance-Related Disorde | 1986 |
Suppression of craving and other signs of dependence in morphine-addicted monkeys by administration of alpha-methyl-para-tyrosine.
Topics: Animals; Female; Fenclonine; Haloperidol; Haplorhini; Humans; Hypothalamus; Injections, Intravenous; | 1972 |
[Intense pentazocine abstinence syndrome. Treatment of a clinical case].
Topics: Administration, Oral; Adult; Butyrophenones; Diazepam; Drug Evaluation; Female; Haloperidol; Humans; | 1974 |
Persisting psychotic states in adolescent drug users.
Topics: Adolescent; Cataplexy; Child, Institutionalized; Chlorpromazine; Delusions; Hallucinations; Hallucin | 1974 |
Non-addictive drug antagonist program in a community setting.
Topics: Adolescent; Adult; Age Factors; Allied Health Personnel; Ambulatory Care; Community Health Services; | 1973 |
[Noxa-disposition relationship in physically explainable psychoses].
Topics: Adult; Age Factors; Body Constitution; Dibenzylchlorethamine; Female; Haloperidol; Humans; Middle Ag | 1973 |
Use of haloperidol to reduce LSD flashbacks.
Topics: Hallucinations; Haloperidol; Humans; Lysergic Acid Diethylamide; Male; Naval Medicine; Psychoses, Su | 1971 |
The stimulant effect of drugs on indocyanine green clearance by the liver.
Topics: Adult; Aged; Anticonvulsants; Densitometry; Drug Therapy; Ear, External; Female; Half-Life; Haloperi | 1972 |
[Complications caused by anonymous preclinical medication].
Topics: Amitriptyline; Antidepressive Agents; Barbiturates; Bromides; Cannabis; Chlordiazepoxide; Delirium; | 1970 |
Drug interactions with anticoagulants.
Topics: Acetaminophen; Animals; Anti-Bacterial Agents; Anticoagulants; Ascorbic Acid; Barbiturates; Blood Co | 1970 |
[A case of chronic piperazine abuse].
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Movement Disorders; Piperazines; Substance-Relat | 1965 |